Related Experiment Video
Updated: May 28, 2026
Laser Microirradiation to Study In Vivo Cellular Responses to Simple and Complex DNA Damage
Published on: January 31, 2018
The role of PARP in DNA repair and its therapeutic exploitation
1UT-MD Anderson Cancer Centre, Department of Gastrointestinal Medical Oncology, 1515 Holcombe Boulevard, Unit 426, Houston, TX 77030, USA.
Abstract:
Historically, PARP inhibitors (PARPi) were developed to potentiate the cytotoxic effect of certain chemotherapeutic agents and are currently being investigated in combination with chemotherapy in diverse cancer types. These agents are also radiosensitisers and clinical trials of PARPi with concurrent radiation are required. It has long been recognised that defective DNA repair pathways lead to tumour susceptibility. Recent studies indicate that tumour cells with defective homologous recombination (HR) repair pathways, the classic example being BRCA mutations, are exquisitely sensitive to PARPi. Defects in HR are not restricted to BRCA-associated tumours and other cancer types may be enriched for HR defects and hence susceptible to PARP inhibition. The identification of predictive markers for sensitivity to PARP inhibition is a priority area for research.
Insights
PARP inhibitors (PARPi) enhance chemotherapy and radiation effects. Tumors with DNA repair defects, like BRCA mutations, show high sensitivity to PARPi, driving research into predictive markers.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Poly (ADP-ribose) polymerase inhibitors (PARPi) potentiate chemotherapy and radiation.
- Defective DNA repair pathways increase tumor susceptibility.
- Homologous recombination (HR) repair defects, such as BRCA mutations, confer sensitivity to PARPi.
Purpose of the Study:
- To explore the role of PARP inhibitors (PARPi) in cancer therapy.
- To investigate the link between DNA repair defects and PARPi efficacy.
- To highlight the need for predictive markers for PARPi sensitivity.
Main Methods:
- Review of historical development and current clinical investigations of PARPi.
- Analysis of studies linking homologous recombination (HR) repair defects to PARPi sensitivity.
- Discussion of the requirement for clinical trials combining PARPi with radiation.
Main Results:
- PARPi are effective in potentiating chemotherapy and act as radiosensitizers.
- Tumors with defective HR repair pathways, including BRCA mutations, are highly sensitive to PARPi.
- HR defects are present in various cancer types beyond BRCA-associated tumors.
Conclusions:
- PARPi represent a promising therapeutic strategy, particularly for tumors with HR deficiencies.
- Clinical trials combining PARPi with chemotherapy and radiation are warranted.
- Identifying predictive biomarkers for PARPi response is a critical research priority.
More Related Videos
07:53Visualization and Quantitative Analysis of Genotoxin-Induced PARP1/PARP2 Activation in Cells Using a Fluorescent Fusion Protein-Based Reporter
Published on: April 17, 2026
06:44Assessment of Global DNA Double-Strand End Resection using BrdU-DNA Labeling coupled with Cell Cycle Discrimination Imaging
Published on: April 28, 2021
Related Concept Videos
01:02Long-patch Base Excision Repair
02:36DNA Damage Can Stall the Cell Cycle
02:36DNA Damage can Stall the Cell Cycle
02:37Restarting Stalled Replication Forks
01:38Nucleotide Excision Repair
Cells are regularly exposed to mutagens—factors in the environment that can damage DNA and generate mutations. UV radiation is one of the most common mutagens and is estimated to introduce a significant number of changes in DNA. These include bends or kinks in the structure, which can block DNA replication or transcription. If these errors are not fixed, the damage can cause mutations, which in turn can result in cancer or disease depending on which sequences are...
01:08Nucleotide Excision Repair